CAR-iNKT cell therapy: mechanisms, advantages, and challenges

Area of Science:

• Cancer immunotherapy
• Cellular therapy
• Immunology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has achieved success in hematologic malignancies but faces limitations in solid tumors.
• Challenges in solid tumors include immunosuppressive microenvironments, antigen heterogeneity, and toxicity.
• Invariant natural killer T (iNKT) cells are being explored as an alternative immune cell platform.

Purpose of the Study:

• To review the application and therapeutic potential of CAR-iNKT cells in cancer immunotherapy.
• To highlight the advantages of CAR-iNKT cells over conventional CAR-T cells for solid tumor treatment.
• To discuss how CAR-iNKT cells can address challenges in solid tumor immunotherapy.

Main Methods:

• Review of existing literature on CAR-T cell therapy and iNKT cell biology.
• Analysis of the unique immunological properties of iNKT cells, including their TCR, antigen recognition, and ability to bridge innate and adaptive immunity.
• Exploration of CAR technology applied to iNKT cells to enhance tumor targeting and overcome solid tumor barriers.

Main Results:

• iNKT cells possess potent antitumor activity and can modulate the tumor microenvironment.
• iNKT cells demonstrate intrinsic resistance to exhaustion and superior tumor infiltration compared to conventional T cells.
• CAR-engineered iNKT cells (CAR-iNKT) show potential for enhanced tumor targeting and overcoming solid tumor challenges.

Conclusions:

• CAR-iNKT cells represent a promising next-generation immunotherapy for solid tumors.
• Their unique properties offer advantages over conventional CAR-T cells in addressing the complex tumor microenvironment of solid tumors.
• Further research into CAR-iNKT cells could lead to novel therapeutic strategies for difficult-to-treat solid cancers.